Agrochemicals company Astec Lifesciences announced Q1FY26 results The Company reported consolidated total income of Rs 91.6 crore in Q1FY26 as compared to Rs 70.3 crore in Q1FY25. The consolidated total income in Q1FY 26 increased by 30.3% over Q1 FY25. The Company reported consolidated EBITDA loss of Rs 10.5 crore in Q1FY26 as compared to loss of Rs 45.3 crore in the same period last year. Commenting on the performance, N B Godrej, Chairman, Astec LifeSciences, said: Astec reported improvement in performance on a year on year basis on the back of improvement in volumes & contribution in its enterprise business. Revenue in enterprise & CDMO businesses increased year on year by 68.2% & 85.7% respectively. This also resulted in reduction of EBITDA losses as compared to Q1 FY25, which also had an impact of write down of Inventories of Rs 18.5 crore. Result PDF